NewsHedge Alert: 9:33:13am Ticker: PBYI
Alert Price: $69.09 Change: – 18.68% within 30-minutes
Catalyst: (news release) Puma Biotechnology (PBYI) said it presented updated results from the phase three clinical trial of PB272, or neratinib, for the extended adjuvant treatment of breast cancer, called the ExteNET trial, in San Antonio, Texas.
The results of the trial demonstrated that treatment with neratinib resulted in a 26% reduction of risk of invasive disease recurrence or death versus placebo. The three-year disease free survival rate for the neratinib arm was 92% and for the placebo arm was 89.9%.